PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
124.50M
Better than EYEN's estimated revenue of 63.90M.
-24.90M
Better than EYEN's estimated ebitda of -36.67M.
0.56
Worse than EYEN's estimated eps of 1.40.
16.74M
Better than EYEN's estimated net income of 1.17M.
-24.90M
Better than EYEN's estimated ebit of -36.87M.
4.61B
Better than EYEN's estimated sg&a expense of 45.22B.
Analyze DCF forecasts for the company and compare them with competitors.
1.03M
Better than EYEN's revenue of 0.00.
-9.97%
Better than EYEN's revenue growth rate of -100.00%.
-33.41M
Worse than EYEN's ebitda of -26.60M.
-3243.20%
Worse than EYEN's ebitda margin of 100.00%.
-34.10M
Worse than EYEN's ebit of -26.91M.
-3311.07%
Worse than EYEN's ebit margin of 100.00%.
699.00K
Worse than EYEN's depreciation of 307.43K.
108.91M
Better than EYEN's total cash of 22.86M.
10573.79%
Better than EYEN's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
10.13M
Worse than EYEN's accounts payable of 1.43M.
983.50%
Worse than EYEN's payables as percentage of revenue of 100.00%.
-366.00K
Worse than EYEN's capital expenditure of -874.75K.
-35.53%
Better than EYEN's capex as percentage of revenue of 100.00%.
4.99%
Better than EYEN's weighted average cost of capital (wacc) of 20.78%.
5.02%
Better than EYEN's cost of equity of 7.67%.
4.08%
Better than EYEN's cost of debt of 22.10%.
-0.23
Better than EYEN's beta of 0.76.
30.07M
Worse than EYEN's diluted shares outstanding of 833.00K.
1.57M
Better than EYEN's total debt of 11.24M.
49.31M
Better than EYEN's total equity of 941.29K.
50.89M
Better than EYEN's total capital of 12.18M.
3.09%
Better than EYEN's debt weighting of 92.27%.
96.91%
Better than EYEN's equity weighting of 7.73%.
-32.98M
Worse than EYEN's ebiat of -26.64M.
-28.05M
Better than EYEN's unlevered free cash flow of -30.66M.
2.00%
Equal to EYEN's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than EYEN's net debt of 9.12M.
71.33M
Better than EYEN's equity value of -11.30M.
2.37
Better than EYEN's equity value per share of -13.56.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.